摘要
二肽基肽酶4(DPP-4)抑制剂是一类治疗糖尿病的新型药物,除有降糖作用外,还有一定的心血管保护作用。同时,DPP-4抑制剂还可以通过降低血脂起到降低心血管事件的风险因素,但对高血压的影响尚不明确。目前关于DPP-4抑制剂(如西格列汀、阿格列汀、利格列汀等)对心血管事件影响的前瞻性研究尚在进行之中,这将进一步完善DPP-4抑制剂对心血管保护作用的相关研究。
Dipeptidyl-peptidase 4（DPP-4） inhibitors are a new class of drugs for the treatment of diabetes. DPP-4 inhibitors have a cardiovascular protective effect in addition to the hypoglycemie effect. And DPP-4 inhibitors could also reduce the ]ipids to reduce the risk of cardiovascular events factors, however, the DPP-4 inhibitors effects on hypertension is not clear. At present, the prospective experiments on effects of DPP-4 inhibitors（ such as sitagliptin, alogliptin, linagliptin）on cardiovascular events are still under way, which will further improve the studies on the cardiovascular protective effects of DPP-4 inhibitors.
出处
《医学综述》
2014年第1期102-105,共4页
Medical Recapitulate
关键词
二肽基肽酶4抑制剂
2型糖尿病
心血管保护
Dipeptidyl-peptidase 4 inhibitor
Type 2 diabetes
Cardiovascular protection
